Lenalidomide (CC-5013)

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects. It has been extensively studied for the treatment of multiple myeloma and myelodysplastic syndrome as well as lymphoproliferative disorders including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. According to recent studies, Lnalidomide promotes and restores immune system function in CLL patients by inducing an overexpression of costimulatory molecules in leukemic lymphocytes to restore the humoral immunity and immunoglobulins production as well as improving the ability of T cells and leukemic cells to form synapses with T lymphocytes.
- Properties
  - Alternative Name
    
    Revlimid,IMiD3,CC 5013,CDC-501,CDC 501; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
    
    CAS Number
    
    191732-72-6
    
    Molecular Formula
    
    C13H13N3O3
    
    Molecular Weight
    
    259.3
    
    Appearance
    
    A solid
    
    Purity
    
    96.25%
    
    Solubility
    
    insoluble in EtOH; insoluble in H2O; ≥100.8 mg/mL in DMSO
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. Ying Jin, Jie Zhou, et al. "Electroacupuncture alleviates the transition from acute to chronic pain through the p38 MAPK/TNF-α signalling pathway in the spinal dorsal horn." Acupunct Med. 2021 Dec;39(6):708-715. PMID:34308662